| Title | Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension |
| Authors | Jing, Zhi-Cheng Strange, Geoff Zhu, Xian-Yang Zhou, Da-Xin Shen, Jie-Yan Gu, Hong Yang, Zhen-Kun Pan, Xin Xiang, Mei-Xiang Yao, Hua Zhao, Dong-Bao Dalton, Brad S. Zhang, Zhuo-Li Wang, Yong Cheng, Xian-Sheng Yang, Yue-Jin |
| Affiliation | Tongji Univ, Dept Pulm Circulat, Shanghai Pulm Hosp, Sch Med, Shanghai 200092, Peoples R China. Monash Univ, Clayton, Vic 3800, Australia. Gen Hosp Shenyang Mil Command, Dept Congenital Heart Dis, Shenyang, Peoples R China. Fudan Univ, Dept Cardiol, Zhongshan Hosp, Shanghai 200433, Peoples R China. Shanghai Jiao Tong Univ, Dept Cardiol, Renji Hosp, Sch Med, Shanghai 200030, Peoples R China. Capital Univ Med Sci, Dept Pediat, Beijing Anzhen Hosp, Beijing, Peoples R China. Ruijin Hosp, Dept Cardiol, Shanghai, Peoples R China. Shanghai Jiao Tong Univ, Dept Cardiol, Shanghai Chest Hosp, Sch Med, Shanghai 200030, Peoples R China. Zhejiang Univ, Dept Cardiol, Affiliated Hosp 2, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China. Guangzhou Gen Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China. Second Mil Med Univ, Dept Rheumatol, Changhai Hosp, Shanghai, Peoples R China. Univ Tasmania, Sch Human Life Sci, Hobart, Tas 7001, Australia. Beijing Univ, Dept Rheumatol, Hosp 1, Beijing 100871, Peoples R China. Beijing Shijitan Hosp, Dept Pulm Vasc Dis, Beijing, Peoples R China. Beijing Fu Wai Hosp, Dept Cardiol, Beijing, Peoples R China. |
| Keywords | pulmonary arterial hypertension bosentan CONGENITAL HEART-DISEASE RECEPTOR ANTAGONIST BOSENTAN EISENMENGER-SYNDROME EXERCISE CAPACITY 1ST-LINE BOSENTAN THERAPY SURVIVAL REGISTRY ADULTS MANAGEMENT |
| Issue Date | 2010 |
| Citation | JOURNAL OF HEART AND LUNG TRANSPLANTATION.2010,29,(2,SI),150-156. |
| Abstract | BACKGROUND: Bosentan has an established role in the management of pulmonary arterial hypertension (PAH). This clinical trial assessed the benefits of bosentan in the Chinese population. METHODS: We investigated the efficacy and safety of bosentan in 92 Chinese citizens (mean +/- standard deviation age, 29.0 +/- 3.8 years) with PAH for a minimum of 12 weeks. All received bosentan (62.5 mg twice daily) for 4 weeks; then, patients who weighed <40 kg received 62.5 mg bosentan twice daily and patients who weighed >40 kg received 125 mg twice daily. All patients were eligible to continue bosentan beyond 12 weeks. The primary end point was a chance in exercise capacity from baseline to 12 and 24 weeks. Secondary end points included a change in World Health Organization (WHO) functional class and changes in cardiopulmonary hemodynamics. RESULTS: At baseline, 66 patients (72%) were in WHO functional class III; presentation was 37 (40%) with idiopathic PAH (iPAH), 34 (37%) with PAH related to congenital heart disease (CHD), and 21 (23%) with PAH related to connective tissue disease (CTD). Exercise capacity increased to 67.8 m after 12 weeks and 92.6 m after 24 weeks (p < 0.001). After 24 weeks, WHO functional class decreased (-0.8 +/- 0.6; p < 0.001), mean pulmonary artery pressure and pulmonary vascular resistance decreased (p < 0.01), ana cardiac output increased (p < 0.001). Twelve patients (13%) experienced at least 1 adverse event. CONCLUSIONS: Bosentan improved exercise capacity, functional class, and cardiopulmonary hemodynamics in this patient cohort and was well tolerated. J Heart Lung Transplant 2010;29:150-6 (C) 2010 International Society for Heart and Lung Transplantation. All rights reserved. |
| URI | http://hdl.handle.net/20.500.11897/401309 |
| ISSN | 1053-2498 |
| DOI | 10.1016/j.healun.2009.09.020 |
| Indexed | SCI(E) |
| Appears in Collections: | 第一医院 |
